More Research Is Needed to Quantify Risks, Benefits, and Cost-Effectiveness of Universal Mupirocin Usage

Clin Infect Dis. 2016 May 1;62(9):1193-4. doi: 10.1093/cid/ciw077. Epub 2016 Feb 21.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Cost-Benefit Analysis*
  • Humans
  • Mupirocin*
  • Risk
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents
  • Mupirocin